Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Celyad   /   celyad 2020

Aandeel Celyad BRU:CYAD.BL, BE0974260896

Laatste koers (eur) Verschil Volume
0,779   +0,009   (+1,17%) Dagrange 0,750 - 0,820 23.797   Gem. (3M) 85K

celyad 2020

Volgen
3.398 Posts
Pagina: «« 1 ... 129 130 131 132 133 ... 170 »» | Laatste | Omlaag ↓
  1. Grote Ogen 10 juli 2020 13:28
    Hmmmm dat verklaart waarom er verkocht wordt....maar goed ik wacht verder rustig af:

    ELYAD SA/ADR (NASDAQ:CYAD) Downgraded to “Sell” at Zacks Investment Research
    Posted by Joseph McCarthy on Jul 10th, 2020

    CELYAD SA/ADR logoCELYAD SA/ADR (NASDAQ:CYAD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports.

    According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “

    CYAD has been the subject of several other research reports. William Blair reiterated a “buy” rating on shares of CELYAD SA/ADR in a report on Monday, June 1st. HC Wainwright reaffirmed a “buy” rating on shares of CELYAD SA/ADR in a research note on Thursday, May 7th. Wells Fargo & Co cut their price objective on CELYAD SA/ADR from $44.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, March 26th. Finally, ValuEngine cut CELYAD SA/ADR from a “strong-buy” rating to a “buy” rating in a report on Friday, May 29th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. CELYAD SA/ADR currently has an average rating of “Buy” and a consensus price target of $23.67.


    Shares of CYAD stock opened at $10.25 on Wednesday. CELYAD SA/ADR has a 1-year low of $4.10 and a 1-year high of $14.98. The company has a 50-day moving average of $10.66 and a two-hundred day moving average of $9.68. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.07.

    Large investors have recently bought and sold shares of the business. UBS Group AG increased its position in shares of CELYAD SA/ADR by 241.2% during the fourth quarter. UBS Group AG now owns 3,064 shares of the company’s stock worth $32,000 after acquiring an additional 2,166 shares during the period. Jane Street Group LLC acquired a new position in CELYAD SA/ADR during the 4th quarter worth $117,000. Morgan Stanley grew its stake in CELYAD SA/ADR by 5.1% during the 1st quarter. Morgan Stanley now owns 39,773 shares of the company’s stock worth $296,000 after purchasing an additional 1,915 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in CELYAD SA/ADR by 4.8% during the 4th quarter. Victory Capital Management Inc. now owns 999,439 shares of the company’s stock worth $10,414,000 after purchasing an additional 45,778 shares during the period. Institutional investors and hedge funds own 7.59% of the company’s stock.

    CELYAD SA/ADR Company Profile

    Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
  2. Grote Ogen 10 juli 2020 13:29
    Sommigen blijven blijkbaar toch nog bij Buy:

    CELYAD SA/ADR (NASDAQ:CYAD) has earned a consensus rating of “Buy” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $20.00.

    CYAD has been the subject of a number of analyst reports. William Blair restated a “buy” rating on shares of CELYAD SA/ADR in a research note on Monday, June 1st. Wells Fargo & Co reduced their price objective on shares of CELYAD SA/ADR from $44.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, March 26th. ValuEngine lowered shares of CELYAD SA/ADR from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 29th. HC Wainwright reiterated a “buy” rating on shares of CELYAD SA/ADR in a research note on Thursday, May 7th. Finally, Zacks Investment Research lowered shares of CELYAD SA/ADR from a “hold” rating to a “sell” rating in a research note on Wednesday.
  11. Noob nr1 14 juli 2020 07:54
    ABM FN) Celyad Oncology heeft goedkeuring van de Amerikaanse FDA gekregen om een Fase 1 studie met CYAD-211 uit te mogen voeren. Dit kondigde het Waalse biotechbedrijf dinsdagochtend aan.

    De shRNA-gebaseerde allogene kandidaat CYAD-211 wordt gebruikt voor de behandeling van patiënten met recidiverende / refractaire multipel myeloom.

    De Fase 1 studie zal tegen het einde van het jaar van start gaan, aldus Celyad.
3.398 Posts
Pagina: «« 1 ... 129 130 131 132 133 ... 170 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee